EUVIMEDEUVIMED entdecken
Crossref

Wells Syndrome (Eosinophilic Cellulitis): Current Clinical, Histopathological, and Therapeutic Aspects

Valentina Broshtilova, Nencho Smilov, Yoanna Velevska-Vatova, Irina Yungareva, Alexander Trenovski, Sonya Marina

International Journal of Clinical Dermatology · 09.12.2025 · 8 (2) · 69-75

DOI: 10.11648/j.ijcd.20250802.15 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Dermatology, online erschienen am 09.12.2025. Verfasst von Valentina Broshtilova und 5 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wells syndrome, also known as eosinophilic cellulitis , is a rare, relapsing inflammatory dermatosis characterized by erythematous and edematous plaques, accompanied by a distinctive histopathological feature known as flame figures. Since its initial description by G. Wells in 1971, fewer than one hundred well-documented cases have been reported in both children and adults. This review summarizes the clinical, histopathological, and therapeutic aspects of Wells syndrome, with particular emphasis on diagnostic challenges and emerging treatment options. A systematic analysis of classical and contemporary literature, including case series and clinical observations, was conducted. The discussion encompasses the clinical presentation, histological characteristics, presumed etiopathogenesis, and therapeutic outcomes. Clinically, the disease manifests as acute-onset erythematous, urticarial, or annular plaques that often resemble infectious cellulitis but fail to respond to antibiotic therapy. Histopathological examination typically reveals a dense eosinophilic infiltrate with flame figures and granulomatous elements. Although the disease course is generally benign, it is prone to recurrence. Systemic corticosteroids remain the mainstay of treatment; however, recurrent or refractory cases may require agents such as dapsone, cyclosporine, or methotrexate. Recent advances include the use of biologic therapies targeting the IL-5 and IL-4/IL-13 pathways—such as omalizumab, mepolizumab and dupilumab—as well as JAK inhibitors, which have shown promising results in improving disease control and reducing relapse frequency. Further research is needed to establish standardized treatment protocols and optimize long-term management strategies.

Zitieren

APA

Broshtilova, V., Smilov, N., Velevska-Vatova, Y., Yungareva, I., Trenovski, A., & Marina, S. (2025). Wells Syndrome (Eosinophilic Cellulitis): Current Clinical, Histopathological, and Therapeutic Aspects. International Journal of Clinical Dermatology, 8(2), 69-75. https://doi.org/10.11648/j.ijcd.20250802.15

Vancouver

Broshtilova V, Smilov N, Velevska-Vatova Y, Yungareva I, Trenovski A, Marina S. Wells Syndrome (Eosinophilic Cellulitis): Current Clinical, Histopathological, and Therapeutic Aspects. International Journal of Clinical Dermatology. 2025;8(2):69-75. doi:10.11648/j.ijcd.20250802.15

BibTeX
@article{Broshtilova2025,
  author = {Broshtilova, Valentina and Smilov, Nencho and Velevska-Vatova, Yoanna and Yungareva, Irina and Trenovski, Alexander and Marina, Sonya},
  title = {Wells Syndrome (Eosinophilic Cellulitis): Current Clinical, Histopathological, and Therapeutic Aspects},
  journal = {International Journal of Clinical Dermatology},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {69--75},
  doi = {10.11648/j.ijcd.20250802.15}
}
Kostenlos starten →